2020 American Transplant Congress
Biomarkers AFP in Combination with AFP-l3 and DCP Predicts Tumor Progression in Treatment Native HCC Patients
Ochsner Health System, New Orleans, LA
*Purpose: Hepatocellular carcinoma (HCC) treatment with locoregional therapy (LRT) is standard treatment to downstage within Milan Criteria. In this study, we retrospectively analyzed early-stage HCC…2020 American Transplant Congress
Bad Actors within Milan Criteria Undergoing OLT- Characterizing Their Pre-Transplant Tumor Behavior and Response to Locoregional Therapy
Columbia University, New York, NY
*Purpose: Orthotopic Liver Transplantation (OLT) remains a curative option for hepatocellular carcinoma (HCC). Disparity between the supply and demand for OLT necessitates the transplant of…2020 American Transplant Congress
The Perioperative Coagulation Profile of Hepatocellular Carcinoma During Liver Transplantation Compared to Patients with Non-Malignant Disease: A Cause or Association for Decreased Blood Product Utilization During Liver Transplantation?
University of Colorado, Aurora, CO
*Purpose: Hepatobiliary malignancies have been associated with hyper-coagulability. However, the impact of hepatocellular carcinoma (HCC) on coagulation during liver transplantation remains less clear. We hypothesize…2020 American Transplant Congress
Shorter Waiting Time Was Associated with Higher Risk of Recurrence of Hepatocellular Carcinoma in Liver Transplantation
*Purpose: Liver transplantation (LT) is an established treatment option for hepatocellular carcinoma (HCC). After 6-month waiting rule was implemented, the impact of wait-listing (WL) time…2020 American Transplant Congress
Waiting List Mortality of Liver Tumors
Division of Transplantation, Massachusetts General Hospital, Boston, MA
*Purpose: Liver transplantation has been approved for hepatocellular carcinoma (HCC), hilar cholangiocarcinoma (CCA) and metastatic neuroendocrine tumors (NET), with the aim to produce similar outcomes…2020 American Transplant Congress
Hepatocellular Carcinoma Locoregional Therapy: A Comparison of Radiologic Treatment Response and Post-Transplant Pathology
*Purpose: Transplantation or resection is the only potentially curative treatment for Hepatocellular Carcinoma (HCC). Locoregional therapy (LRT) is used exclusively in non-transplant candidates or as…2020 American Transplant Congress
Effect of 2015 T2 Hepatocellular Carcinoma Exception Policy Implementation on Waitlist Time and Tumor Characteristics
*Purpose: A United Network for Organ Sharing (UNOS) policy change in 2015 created a 6-month delay in the receipt of T2 hepatocellular carcinoma (HCC) exception…2020 American Transplant Congress
The Impact of Initial Alpha-Fetoprotein >100 but <1,000 ng/mL and Pre-Transplant alpha-Fetoprotein Reduction on Outcomes after Liver Transplant in Patients with Hepatocellular Carcinoma
1Department of Medicine, UCSF, San Francisco, CA, 2Department of Medicine, USC, Los Angeles, CA
*Purpose: Under current UNOS policy, hepatocellular carcinoma (HCC) patients with alpha-fetoprotein (AFP) >1,000 ng/mL are required to show a reduction in AFP to 100 but2020 American Transplant Congress
Living Donor Liver Transplantation for Hepatocellular Carcinoma Beyond UCSF Criteria: Tumor Biology Not the Tumor Number Decide the Long Term Outcome- A Single Center Retrospective Analysis of Using Extended Criteria
Organ Transplantation Center, China Medical University Hospital, Taichung, Taiwan
*Purpose: HCC is the fifth most common cancer and the third most frequent cause of cancer deaths worldwide. After its introduction for LT in HCC…2020 American Transplant Congress
Early Recurrence Of Hepatocellular Carcinoma Following Transplantation: Risk Score From A Multi-institutional Study Of > 3000 Patients
*Purpose: Early recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) carries a poor prognosis. We aimed to develop a risk score for early HCC…
American Transplant Congress abstracts